| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 41899 |
Unlisted procedure, dentoalveolar structures |
775 |
585 |
$2.25M |
| G0378 |
Hospital observation service, per hour |
1,510 |
1,299 |
$803K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,632 |
3,258 |
$561K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,575 |
4,086 |
$410K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,437 |
1,326 |
$83K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
338 |
299 |
$72K |
| 80053 |
Comprehensive metabolic panel |
8,856 |
7,165 |
$70K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,893 |
1,556 |
$42K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,195 |
1,991 |
$21K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,314 |
6,833 |
$18K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,412 |
944 |
$16K |
| 71046 |
Radiologic examination, chest; 2 views |
1,805 |
1,645 |
$14K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
463 |
417 |
$12K |
| J1815 |
Injection, insulin, per 5 units |
371 |
179 |
$11K |
| 71045 |
Radiologic examination, chest; single view |
1,359 |
1,236 |
$7K |
| J3490 |
Unclassified drugs |
1,477 |
933 |
$6K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
392 |
340 |
$6K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,374 |
3,183 |
$6K |
| 87631 |
|
285 |
269 |
$5K |
| 81001 |
|
2,633 |
2,328 |
$5K |
| 85027 |
|
1,821 |
1,362 |
$4K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
16 |
12 |
$4K |
| 93971 |
|
29 |
26 |
$4K |
| 84484 |
|
3,508 |
2,414 |
$3K |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,178 |
538 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,033 |
915 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
418 |
373 |
$3K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
92 |
89 |
$3K |
| 83605 |
|
682 |
542 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
676 |
645 |
$2K |
| J2704 |
Injection, propofol, 10 mg |
1,376 |
1,043 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
53 |
38 |
$2K |
| 84703 |
|
1,292 |
1,079 |
$2K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
63 |
57 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,061 |
1,650 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
17 |
17 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
417 |
296 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,550 |
1,996 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
751 |
583 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
83 |
59 |
$1K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,295 |
779 |
$899.82 |
| 97161 |
|
52 |
43 |
$898.50 |
| 94760 |
|
73 |
42 |
$818.91 |
| 81003 |
|
702 |
598 |
$795.91 |
| A9270 |
Non-covered item or service |
26,246 |
5,034 |
$779.97 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,405 |
1,054 |
$716.37 |
| 86850 |
|
141 |
114 |
$693.45 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
355 |
248 |
$574.91 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
387 |
319 |
$475.35 |
| C9113 |
Injection, pantoprazole sodium, per vial |
114 |
77 |
$467.48 |
| 83690 |
|
1,391 |
1,284 |
$442.84 |
| 85610 |
|
1,113 |
910 |
$425.23 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
144 |
83 |
$423.19 |
| 87040 |
|
96 |
51 |
$380.21 |
| J7070 |
Infusion, d5w, 1000 cc |
491 |
337 |
$278.02 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
539 |
469 |
$212.24 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
222 |
186 |
$205.61 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
767 |
584 |
$195.92 |
| 83880 |
|
245 |
226 |
$138.18 |
| 84443 |
Thyroid stimulating hormone (TSH) |
345 |
302 |
$133.98 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
104 |
52 |
$131.90 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
81 |
64 |
$125.90 |
| J7050 |
Infusion, normal saline solution, 250 cc |
165 |
129 |
$125.17 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
18 |
14 |
$99.94 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
34 |
25 |
$86.79 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
16 |
14 |
$72.93 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
664 |
573 |
$49.09 |
| 83735 |
|
310 |
235 |
$38.13 |
| 85730 |
|
204 |
168 |
$29.64 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
31 |
18 |
$25.02 |
| 86900 |
|
102 |
84 |
$23.09 |
| 86901 |
|
102 |
84 |
$23.09 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
56 |
40 |
$18.50 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
32 |
28 |
$8.83 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
55 |
50 |
$0.14 |
| G1012 |
Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program |
1,092 |
802 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
37 |
36 |
$0.00 |
| 80143 |
|
40 |
37 |
$0.00 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
26 |
25 |
$0.00 |
| 80179 |
|
27 |
24 |
$0.00 |
| 82077 |
|
44 |
38 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
59 |
52 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
258 |
224 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
45 |
31 |
$0.00 |
| 84132 |
|
16 |
15 |
$0.00 |